Novartis' compassionate use requests worldwide: Just 0.5% came from lower-middle- and low-income countries
From 2018 through 2020, Novartis received almost 32,000 requests from 110 countries to use one of the company’s experimental drugs (known as “compassionate use” requests, or in the US, “expanded access“) for patients with serious or life-threatening medical conditions.
But when the requests were divided by each participating country’s GDP, the Novartis researchers found that just 0.5% of the requests came from lower-middle- and lower-income countries. When stratified by gross national income, only 3% of the requests came from lower-middle- and lower-income countries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
